Background--There is emerging evidence that adjuvant treatments for breast cancer negatively impact cardiorespiratory fitness (CRF) or VO 2max , a key predictor of cardiovascular risk. Although a number of studies have measured CRF in breast cancer patients, there is currently limited data regarding expected CRF values in this patient population. Given that CRF is a poor prognostic sign and recently highlighted as a key measure to standardize by the American Heart Association, we sought to review the available literature on CRF among breast cancer patients.
trastuzumab to the management of human epidermal growth factor receptor (HER)-2-positive early breast cancer has further increased clinical and subclinical cardiotoxicity rates. 12, 13 There is emerging evidence that adjuvant therapy for breast cancer can also significantly affect cardiorespiratory fitness (CRF). CRF as measured by VO 2max assesses global cardiovascular function, cardiopulmonary reserve, and efficiency of oxygen transport and utilization and can unmask compensatory mechanisms of abnormal cardiac function as well as defects in other vital organs.
14,15 A number of studies have shown that VO 2max is impaired in breast cancer patients compared with healthy controls. 5, 6, 16, 17 This finding is of major concern given that low VO 2max is associated with higher mortality among more-advanced stage breast cancer patients. 17 Despite evidence that low VO 2max is a poor prognostic sign, there is currently little known regarding VO 2max levels among breast cancer patients. Knowledge of VO 2max values in breast cancer is of timely importance as the American Heart Association is calling for the development of a national adult database of CRF, given the critical impact of CRF on cardiovascular morbidity, all-cause mortality, 18 and cancer survival. 17, 19 Moreover, VO 2max values would enable healthcare providers to define levels of CRF associated with poor health outcomes in the breast cancer population, elucidate therapy-related decrements in CRF, and help target appropriately timed interventions.
To address this gap in the literature, we identified 27 clinical trials and observational studies measuring VO 2max in the pre-or post-adjuvant treatment setting for breast cancer. We compared mean VO 2max values of female breast cancer patients in 6 studies that measured VO 2max before adjuvant therapy and 21 studies that measured VO 2max after adjuvant therapy was completed. We then compared mean VO 2max values in female breast cancer patients with the VO 2max values of healthy, sedentary, and active, endurance-trained controls. Secondary variables of interest included patients' age, body mass index (BMI), and study type and period.
Methods
We performed a MEDLINE search for citations of peer reviewed clinical studies measuring CRF in breast cancer patients. We used the following search terms: cardiorespiratory fitness or fitness or exercise capacity and breast cancer. We excluded studies not printed in the English language. We included observational studies and clinical trials involving exercise interventions in which CRF was measured in female breast cancer patients. Clinical trials consisted of both randomized controlled trials (RCTs) and exercise intervention studies, each of which examined the effects of exercise interventions on CRF as well as other variables in breast cancer patients. RCTs also measured outcomes in control groups consisting of women without a history of breast cancer, whereas exercise intervention studies did not contain control groups. Studies were only included if CRF was measured using VO 2max [mL/(kg min) or L/min] and if CRF was measured within 5 years of completion of adjuvant therapy. For RCTs and exercise intervention studies, we reported mean baseline VO 2max values and associated SDs before the initiation of exercise training.
Twenty-six clinical trials and observational studies that measured VO 2max in female breast cancer patients pre-or post-adjuvant therapy were identified. Because Schneider et al 20 measured VO 2max in pre-and post-adjuvant therapy settings, the 2 subsets were treated as independent populations, making the effective sample size 27 studies. A control population of healthy women was identified from a previously performed meta-analysis by 21 Estimated rates of decline for sedentary, active, and endurance-trained women were À3.5 mL/(kg min), À4.4 mL/(kg min), and À6.2 mL/ (kg min) per decade, respectively. 21 The algorithms in the Fitzgerald report have been previously used and compared in other breast cancer populations. 17 The majority of studies (16 of 27) measured CRF using a treadmill walking test and either a Bruce, Balke, or Naughton protocol. Of the remaining studies, 8 measured CRF with an electronic cycle ergometer, 1 measured CRF with a stepping ergometer, and 2 did not report the exercise equipment used to measure CRF. VO 2max was measured directly from expired gas analysis during maximal effort in 14 studies and estimated using previously derived equations in 13 studies. A majority of studies reported mean VO 2max in mL/(kg min), but for studies that reported mean VO 2max in L/min and also reported mean weight in kg, a conversion was done using the standard method of division of random variables for both the mean and SD. 22 Of the 1856 patients studied in this review, To accurately compare VO 2max pre-and post-adjuvant therapy with that of controls, the inverse-variance method of weighting assuming a random-effects model was used. 31 Fitzgerald et al 21 reported that the weighted and unweighted means for the control group were not different; thus, the mean VO 2max used for the control group was un-weighted. The standard error and 95% confidence interval were also calculated according to the guidelines of Borenstein and Higgins.
31
Raw mean and SD values for VO 2max (mL/(kg min)], age, and BMI were summarized for each study. Fisher's exact tests were used to compare the distribution of study type and therapy class, and Student t tests were used to compare the mean age and BMI between pre-and post-adjuvant therapy breast cancer studies. Meta-regression was used to explore the linear relationship between the weighted mean VO 2max of each study, age, BMI, study type, and subgroup (pre-or postadjuvant therapy). BMI was not reported for 5 studies. A sensitivity analysis was done to determine if imputation with the mean BMI would change the results of the linear regression. Imputation did not change the results, and as such, missing BMI values were replaced with the mean BMI for all other studies so that all 27 studies could be included in the meta-regression.
Tests for heterogeneity were conducted to verify the appropriateness of meta-analysis for mean values of VO 2max for all breast cancer studies and for pre-adjuvant therapy studies and post-adjuvant therapy studies separately. Methods described in Higgins and Thompson 32 were used to carry out this analysis. The H statistic, a modified Cochran's v2 test (Q test) statistic that does not intrinsically depend on the number of studies, was calculated, with H=1 indicating homogeneity.
32
Results
Fitness in the Preadjuvant and Postadjuvant Setting
Twenty-seven studies measuring VO 2max in breast cancer patients were identified between 2001 and 2013, involving a total of 1856 female participants with mean ages ranging from 47 to 59 years. The 6 studies that reported VO 2max prior to adjuvant therapy as well as the 21 studies that reported VO 2max after completion of adjuvant therapy are summarized in Table 1 . Weight percent by subgroup (pretherapy and posttherapy) and weight percent overall of each of the 27 studies are also shown in Table 1 . Table 2 shows descriptive variables from all 27 studies as well as a comparison among the overall and pre-and postadjuvant therapy breast cancer groups. Overall, 20% were RCTs, 22% were observational studies, and 48% were exercise intervention studies. In the preadjuvant setting, 33% were RCTs, and 67% were exercise interventions. Of the studies performed in the postadjuvant setting, 29% were RCTs, 29% were observational studies, and 43% were exercise interventions. Adjuvant therapy included chemotherapy in 78% (predominantly anthracycline-based), radiotherapy in 56%, and hormonal therapy in 33% of patients.
The mean age and BMI for all breast cancer studies were 52AE4 years and 28AE2 kg/m 2 . The mean age was similar in the pre-and post-adjuvant therapy settings (P=0.33, Table  2 ). The weighted mean VO 2max before adjuvant therapy was 24.6 mL/(kg min). For the 21 studies reporting VO 2max after adjuvant therapy, the weighted mean VO 2max was 22.2 mL/ (kg min). The VO 2max in the postadjuvant setting was 10% lower [À2.4 mL/(kg min)] than the mean VO 2max value assessed at the beginning of adjuvant therapy. The mean BMI measured after adjuvant therapy was completed was 2.6 kg/m 2 higher than the BMI prior to adjuvant therapy (28.4AE2 kg/m 2 versus 25.8AE1 kg/m 2 , P=0.009). Table 3 contains the results of the linear meta-regression examining the relationship between age, BMI, study type and period, and weighted mean VO 2max levels. There was no evidence for an association between weighted mean VO 2max and the study variables of interest such as age and BMI (P>0.05 for all). We also performed a test for heterogeneity 
Discussion
The current review demonstrates impairment in VO 2max among female breast cancer patients compared with healthy controls, as well as lower VO 2max depending on the timing of measurement in relation to breast cancer treatment status. These data suggest existing normative CRF values in healthy women may not be representative of breast cancer populations. Based on our previous work, the decline in CRF appears sustained in breast cancer patients even 7 years after treatment compared with age-matched controls. 46 These findings are of key importance given even small differences in CRF [eg, 1 MET or 3.5 mL/(kg min)] are associated with a significantly higher risk for cardiovascular mortality (%18%).
47,48
The reason for impairment in CRF is likely multifactorial, involving multiple organ components of oxygen transport. Of the major components of oxygen transport-namely, pulmonary, cardiac, vascular, and skeletal muscle function, a limitation in cardiac function is the most well studied in breast cancer patients. Chemotherapeutic agents used in breast cancer management are associated with both shortand long-term cardiac complications, which can ultimately lead to congestive heart failure. 49 Anthracycline-based adjuvant chemotherapy in particular carries a substantial longterm risk of heart failure. The mechanism of action of anthracyclines involves intercalation between DNA base pairs, inhibition of DNA topoisomerase II with subsequent blocking of replication and transcription, and the generation of iron- mediated oxygen free radicals that damage DNA as well as proteins and cell membranes. 50 These oxygen free radicals are thought to play a central role in the evolution of the cardiotoxic effects of anthracyclines. 8 Moreover, several lines of evidence suggest that cytotoxic damage caused by anthracyclines leads to compensatory alterations in autonomic tone, which may have important implications for heart rate reserve and CRF. 51, 52 Radiotherapy used to treat breast cancer can cause cardiac perfusion defects that are associated with abnormalities in regional wall motion. 53 Furthermore, radiotherapy-induced cardiotoxicity is amplified by the use of adjuvant systemic chemotherapy-particularly anthracycline-based regimens 54 and newer agents such as trastuzumab. 55 Jones et al 17 has previously shown that mean VO 2max is markedly impaired in a population of breast cancer patients despite normal cardiac function (as indicated by LVEF ≥50%). This important finding suggests that injury to other components of oxygen transport (ie, pulmonary, hematologic, vascular, and skeletal muscle function) must contribute to CRF decline. 17 In particular, incidental radiation to the lungs during radiotherapy for breast cancer causes fibrosis and a subsequent impairment in pulmonary gas exchange. 56 Anemia, a frequent complication of treatment while undergoing therapy, 57 reduces oxygen delivery to muscle cells. 58 Dolan et al 16 found a significant correlation between hemoglobin levels and percent change in VO 2max in women receiving adjuvant therapy for breast cancer. Both radiotherapy and chemotherapy for breast cancer, especially anthracyline-containing chemotherapy, cause increases in reactive oxygen species generation, which can lead to endothelial injury, endothelial dysfunction, vascular remodeling, and increased arterial stiffness, 59 further affecting oxygen delivery. Finally, preclinical studies have shown that anthracyclines impair both maximal twitch force and muscle relaxation. 60, 61 Such impairments in skeletal muscle function decrease oxygen utilization and thereby contribute to reduced CRF. To compound the effects of chemotherapy, numerous studies have also shown that chemotherapy negatively affects skeletal muscle mass in cancer patients. Although chemotherapy is associated with weight gain among breast cancer patients, [62] [63] [64] [65] [66] [67] chemotherapy-induced weight gain tends to occur in the absence of gains in muscle mass or in the presence of muscle loss and can lead to the development of sarcopenic obesity. 66 Importantly, the summation of these insults decreases cardiopulmonary reserve and increases the susceptibility of female breast cancer patients to late-occurring adverse cardiovascular effects and premature mortality. This phenomenon has been labeled the "multiple hit hypothesis" by Jones et al. 49 In keeping with this hypothesis, women with breast cancer in the current review at 50 years of age had a similar CRF to sedentary, 60-year-old women without a history of breast cancer (Figure 2 ). This finding points to an accelerated aging process among female breast cancer patients that can negatively affect CRF and potentially prognosis. Recent evidence suggests that exercise training is an effective intervention to improve CRF as well as quality of life, We analyzed data presented in 27 selected clinical studies with patient populations ranging from 7 to 257 women. Although we were able to draw several conclusions about CRF in breast cancer patients based on these studies, further work is required to assess CRF in ethnically diverse populations at multiple different time points in breast cancer treatment. Importantly, the timing of these decrements and potential recovery can be determined with prospective studies evaluating sequential changes in CRF across patient populations receiving adjuvant therapy regimens. 46 For exercise training interventions to maximally decrease cardiovascular risk in the breast cancer population, interventions should be used before, during, and after treatment, as well as specifically at the time of greatest CRF decline. Other therapeutic modalities, such as statin therapy, angiotensin-converting enzyme inhibitors, and b-blockers, should also be considered in the setting of cardiac dysfunction. In summary, breast cancer patients are subjected to sequential cardiovascular insults throughout their treatment regimens that decrease their CRF and increase their susceptibility to premature cardiovascular mortality compared with the general population. 17, 49 CRF has been shown to be a strong predictor of the adverse health outcomes that can result from breast cancer treatment regimens. Normative VO 2max data for this patient population will allow healthcare providers to predict which patients are at particular risk for late-occurring cardiotoxicity that may be amenable to exercise interventions. This is of key importance given that exercise training can ameliorate impairments in VO 2max and may thereby have the potential to enhance prognosis in breast cancer patients and in other cancer patients as well. 2, 68 
